The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Prolonged Replication of a Type 1 Vaccine-Derived Poliovirus in an Immunodeficient Patient
Open accessAbstract
VP1 sequences were determined for poliovirus type 1 isolates obtained over a 189-day period from a poliomyelitis patient with common variable immunodeficiency syndrome (a defect in antibody formation). The isolate from the first sample, taken 11 days after onset of paralysis, contained two poliovirus populations, differing from the Sabin 1 vaccine strain by ∼10%, differing from diverse type 1 wild polioviruses by 19 to 24%, and differing from each other by 5.5% of nucleotides. Specimens taken after day 11 appeared to contain only one major poliovirus population. Evolution of VP1 sequences at synonymous third-codon positions occurred at an overall rate of ∼3.4% per year over the 189-day period. Assuming this rate to be constant throughout the period of infection, the infection was calculated to have started ∼9.3 years earlier. This estimate is about the time (6.9 years earlier) the patient received his last oral poliovirus vaccine dose, approximately 2 years before the diagnosis of immunodeficiency. These findings may have important implications for the strategy to eliminate poliovirus immunization after global polio eradication.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The persistence of these viruses in immunocompromised individuals may compromise polio eradication efforts.”
From The Fight against Poliovirus Is Not Over (2023) · cites this paper as [107]
In the citing paper
“Recent reports describing highly divergent VDPVs associated with chronic poliovirus infections (10, 69, 88, 90, 113, 123, 216, 223) or with polio outbreaks (84, 169, 177, 226) underscored the earlier concerns and challenged the critical assumption that OPV-derived viruses would not long persist in the community.”
From VACCINE-DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO ERADICATION (2005) · cites this paper as [88]
In the citing paper
“Most RNA viruses have highly mutable genomes that are potentially capable of rapid evolution, many of orders of magnitude faster than the genomes of DNA viruses or cellular organisms (41, 45), and polioviruses are among the most rapidly evolving of all RNA viruses (60, 88, 108, 117, 185, 226).”
From VACCINE-DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO ERADICATION (2005) · cites this paper as [88]
In the citing paper
“Nucleotide substitutions ( > 80% of which in the coding region are to synonymous codons) accumulate at an overall rate of ∼ 1% per year at all sites, and at ∼ 3% per year at synonymous sites (10, 60, 85, 88, 108, 117).”
From VACCINE-DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO ERADICATION (2005) · cites this paper as [88]
In the citing paper
“They also appear to be largely independent of immune selection, as evolution rates are similar during prolonged replication in immunodeficient patients (10, 88, 117, 223) and during widespread circulation (60, 84, 85, 108).”
From VACCINE-DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO ERADICATION (2005) · cites this paper as [88]
In the citing paper
“Other CVID patients developed paralysis several years after receipt of the implicated OPV dose (typically the last dose) (10, 88, 223).”
From VACCINE-DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO ERADICATION (2005) · cites this paper as [88]
In the citing paper
“Symptoms of immunodeficiency typically become evident later in life, usually in the second and third decades, even though prolonged poliovirus infections may have begun years before the diagnosis of CVID (10, 88, 223).”
From VACCINE-DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO ERADICATION (2005) · cites this paper as [88]
In the citing paper
“the neutralizing antigenic sites of iVDPV isolates are frequently highly divergent and variable, and immunodeficient prolonged excretors may be infected with more than one antigenic variant”
From VACCINE-DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO ERADICATION (2005) · cites this paper as [88]
In the citing paper
“Some iVDPV isolates are highly divergent (∼90% VP1 sequence identity to the parental OPV strain), suggesting that the chronic poliovirus infections had persisted for 10 years or more (25, 68).”
From Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993 (2003) · cites this paper as [25]
In the citing paper
“In the rapidly evolving poliovirus genome (16, 25, 32, 35), variable sites (which represent ∼33% of total VP1 nucleotides, primarily at positions of codon degeneracy) saturate within ∼30 years.”
From Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993 (2003) · cites this paper as [25]
In the citing paper
“Such sequence relationships are typical among isolates of locally circulating wild polioviruses (32, 55) and cVDPVs (22) but not among OPV-like or iVDPV isolates from different patients, which generally follow independent pathways of divergence from the vaccine strain (22, 25, 35; R. Park, unpublished results).”
From Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993 (2003) · cites this paper as [25]
In the citing paper
“The VP1 evolution rate estimated from the slope of the regression line was (2.47 ± 0.69) × 10−2 substitutions per synonymous site per year, approximately 80% of the rate observed for circulating wild type 1 polioviruses (16, 25, 32).”
From Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993 (2003) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kimura, M. (1980) · Journal of Molecular Evolution · doi:10.1007/bf01731581 · Cited by 29,778
PHYLIP-Phylogeny inference package (Version 3.2)
Felsenstein, J. (1989) · Cladistics · Cited by 17,682
The rapid generation of mutation data matrices from protein sequences
Jones, D. T., Taylor, W. R., & Thornton, J. M. (1992) · Computer applications in the biosciences · doi:10.1093/bioinformatics/8.3.275 · Cited by 7,003
RNA VIRUS MUTATIONS AND FITNESS FOR SURVIVAL
Domingo, E., & Holland, J. J. (1997) · Annual Review of Microbiology · doi:10.1146/annurev.micro.51.1.151 · Cited by 1,514
Three-Dimensional Structure of Poliovirus at 2.9 Å Resolution
Hogle, J. M., Chow, M., & Filman, D. J. (1985) · Science · doi:10.1126/science.2994218 · Cited by 1,267
Holtzman, D. J., Powell‐Griner, E., Bolen, J. C., & Rhodes, L. (2000) · PubMed · Cited by 1,110
The Primary Immunodeficiencies
Rosen, F. S., Cooper, M. D., & WEDGWOOD, R. J. P. (1984) · New England Journal of Medicine · doi:10.1056/nejm198408023110506 · Cited by 1,097
Chronic Enteroviral Meningoencephalitis in Agammaglobulinemic Patients
McKinney, R. E., Katz, S. L., & Wilfert, C. M. (1987) · Clinical Infectious Diseases · doi:10.1093/clinids/9.2.334 · Cited by 450
Lederman, H. M., & Winkelstein, J. A. (1985) · Medicine · doi:10.1097/00005792-198505000-00001 · Cited by 411
Geographic distribution of wild poliovirus type 1 genotypes
Rico-Hesse, R., Pallansch, M. A., Nottay, B. K., & Kew, O. M. (1987) · Virology · doi:10.1016/0042-6822(87)90001-8 · Cited by 327
Self-citation
Research works printed but not linked: 2
- Más Lago P. Louzará C. Beltrán J. Jacobo M. Palomera R. Circulación de poliovirus en la población infantil de Cuba.Bol. Oficina Sanit. Panam.871975443449
- Sutter R. W. Prevots R. Vaccine-associated paralytic poliomyelitis among immunodeficient persons.Infect. Med.111994426438
Cited by
Sorted by citations
Items 101–200 of 212
Potential Future Use, Costs, and Value of Poliovirus Vaccines
Thompson, K. M., & Kalkowska, D. A. (2020) · Risk Analysis · doi:10.1111/risa.13557 · Cited by 31
Khetsuriani, N., Helfand, R. F., Pallansch, M. A., Kew, O. M., Fowlkes, A. L., Oberste, M. S., Tukei, P. M., Muli, J., Makokha, E. P., & Gary, H. E. (2009) · BMC Infectious Diseases · doi:10.1186/1471-2334-9-136 · Cited by 30
Self-citationGeneration and analysis of an RNA vaccine that protects against coxsackievirus B3 challenge
Hunziker, I. P., Harkins, S., Feuer, R., Cornell, C. T., & Whitton, J. L. (2004) · Virology · doi:10.1016/j.virol.2004.09.035 · Cited by 30
Prevalence of vaccine-derived polioviruses in sewage and river water in South Africa
Pavlov, D. N., van Zyl, W. B., Heerden, J. V., Grabow, W. O. K., & Ehlers, M. M. (2005) · Water Research · doi:10.1016/j.watres.2005.05.027 · Cited by 30
Search for poliovirus long-term excretors among patients affected by agammaglobulinemia
Fiore, L., Plebani, A., Buttinelli, G., Fiore, S., Donati, V., Marturano, J., Soresina, A., Martire, B., Azzari, C., Nigro, G., et al. (2004) · Clinical Immunology · doi:10.1016/j.clim.2003.11.011 · Cited by 29
Cassemiro, K. M. S. D. M., Burlandy, F. M., Barbosa, M. R. F., Chen, Q., Jorba, J. C., Hachich, E. M., Sato, M. I. Z., Burns, C. C., & da Silva, E. E. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152251 · Cited by 27
Polio eradication: finishing the job and protecting the investment.
Heymann, D. L. (2004) · Europe PMC (PubMed Central) · doi:10.1590/s0042-96862004000100002 · Cited by 28
Kalkowska, D. A., Pallansch, M. A., & Thompson, K. M. (2019) · Epidemiology and Infection · doi:10.1017/s095026881900181x · Cited by 27
Self-citationRetrospective Characterization of a Vaccine-Derived Poliovirus Type 1 Isolate from Sewage in Greece
Dedepsidis, E., Kyriakopoulou, Z., Pliaka, V., Kottaridi, C., Bolanaki, E., Levidiotou-Stefanou, S., Komiotis, D., & Markoulatos, P. (2007) · Applied and Environmental Microbiology · doi:10.1128/aem.00535-07 · Cited by 27
Hovi, T., Lindholm, N., Savolainen, C., Stenvik, M., & Burns, C. C. (2004) · Journal of General Virology · doi:10.1099/vir.0.19518-0 · Cited by 27
Zhang, Y., Wang, H., Zhu, S., Li, Y., Li, S., Liu, Y., Liu, G., Nishimura, Y., Chen, L., Yan, D., et al. (2009) · Journal of General Virology · doi:10.1099/vir.0.014258-0 · Cited by 25
Dowdle, W. R., Featherstone, D. A., Birmingham, M. E., Hull, H. F., & Aylward, R. B. (1999) · Virus Research · doi:10.1016/s0168-1702(99)00044-1 · Cited by 26
Characterization of CHAT and Cox Type 1 Live-Attenuated Poliovirus Vaccine Strains
Martín, J. E.-S., & Minor, P. D. (2002) · Journal of Virology · doi:10.1128/jvi.76.11.5339-5349.2002 · Cited by 25
Foiadelli, T., Savasta, S., Battistone, A., Kota, M., Passera, C., Fiore, S., Bino, S., Amato, C., Lozza, A., Marseglia, G. L., et al. (2016) · BMC Infectious Diseases · doi:10.1186/s12879-016-1587-y · Cited by 24
van der Sanden, S., Pallansch, M. A., van de Kassteele, J., El-Sayed, N., Sutter, R. W., Koopmans, M., & van der Avoort, H. (2009) · Journal of Virology · doi:10.1128/jvi.02388-08 · Cited by 24
Self-citationTherapeutic Strategies in Common Variable Immunodeficiency
Sewell, W. A. C., Buckland, M. S., & Jolles, S. R. A. (2003) · Drugs · doi:10.2165/00003495-200363130-00003 · Cited by 24
Molecular Mechanisms of Poliovirus Variation and Evolution
Agol, V. I. (2006) · Current Topics in Microbiology and Immunology · doi:10.1007/3-540-26397-7_8 · Cited by 73
Inactivated poliovirus vaccine and the final stages of poliovirus eradication
Hovi, T. (2001) · Vaccine · doi:10.1016/s0264-410x(00)00515-6 · Cited by 23
Sutter, R. W., Tangermann, R. H., Aylward, R. B., & Cochi, S. L. (2001) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(05)70267-1 · Cited by 24
Self-citationImmunodeficiency-associated Vaccine-Derived Poliovirus Type 3 in Infant, South Africa, 2011
Gumede, N., Muthambi, V., & Schoub, B. D. (2012) · Emerging infectious diseases · doi:10.3201/eid1806.120037 · Cited by 21
Highly Divergent Type 2 and 3 Vaccine-Derived Polioviruses Isolated from Sewage in Tallinn, Estonia
Al‐Hello, H., Jorba, J. C., Blomqvist, S., Raud, R., Kew, O. M., & Roivainen, M. (2013) · Journal of Virology · doi:10.1128/jvi.01174-13 · Cited by 21
Self-citationQuasispecies Dynamics and Evolution of Foot-and-Mouth Disease Virus
Ruiz-Jarabo, C. M., Domingo, E., García‐Arriaza, J., Arias, A., & Escarmı́s, C. (2004) · CRC Press eBooks · doi:10.1201/9781420037968.ch10 · Cited by 21
Thompson, K. M., & Badizadegan, K. (2024) · Expert Review of Vaccines · doi:10.1080/14760584.2024.2361060 · Cited by 21
Sutter, R. W., Kew, O. M., Cochi, S. L., & Aylward, R. B. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35761-6.00048-1 · Cited by 22
Self-citationNucleotide substitution rates of HIV-1
Suzuki, Y., Yamaguchi, Y., & Gojobori, T. (2000) · Aids Reviews · Cited by 20
Dunn, J. J., Romero, J. R., Wasserman, R. L., & Rotbart, H. A. (2000) · The Journal of Infectious Diseases · doi:10.1086/315685 · Cited by 19
Poliovirus vaccine strains detected in stool specimens of immunodeficient children in South Africa
Pavlov, D. N., van Zyl, W. B., Kruger, M., Blignaut, L., Grabow, W. O. K., & Ehlers, M. M. (2005) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2005.08.011 · Cited by 18
Prevalence of vaccine-derived polioviruses in stools of immunodeficient children in South Africa
Pavlov, D. N., van Zyl, W. B., Heerden, J. V., Kruger, M., Blignaut, L., Grabow, W. O. K., & Ehlers, M. M. (2006) · Journal of Applied Microbiology · doi:10.1111/j.1365-2672.2006.03020.x · Cited by 18
Limited and Localized Outbreak of Newly Emergent Type 2 Vaccine-Derived Poliovirus in Sichuan, China
Yan, D., Zhang, Y., Zhu, S., Chen, N., Li, X., Wang, D., Ma, X., Zhu, H., Tong, W., & Xu, W. (2014) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00196-14 · Cited by 17
Mogotsi, M. T., Mwangi, P. N., Bester, P. A., Mphahlele, M. J., Seheri, M. L., O’Neill, H. G., & Nyaga, M. M. (2020) · Viruses · doi:10.3390/v12111260 · Cited by 17
Driss, N., Mellouli, F., Yahia, A. B., Touzi, H., Barbouche, M., Triki, H., & Béjaoui, M. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.01122-14 · Cited by 16
Polio eradication in India: Progress, but environmental surveillance and vigilance still needed
Chatterjee, A., Vidyant, S., & Dhole, T. N. (2013) · Vaccine · doi:10.1016/j.vaccine.2012.12.060 · Cited by 16
Towards global poliomyelitis eradication: The successes and challenges for a developed country
Wood, N. J., & Thorley, B. R. (2003) · Journal of Paediatrics and Child Health · doi:10.1046/j.1440-1754.2003.00263.x · Cited by 15
Zhang, Y., Zhang, F., Zhu, S., Chen, L., Yan, D., Wang, D., Tang, R., Zhu, H., Hou, X., An, H., et al. (2009) · Archives of Virology · doi:10.1007/s00705-009-0564-9 · Cited by 15
Romanenkova, N. I., Guillot, S., Rozaeva, N. R., Crainic, R., Бичурина, М. А., & Delpeyroux, F. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.00017-06 · Cited by 16
Community-Acquired Poliovirus Infection in Children with Primary Immunodeficiencies in Tunisia
Triki, H., Barbouche, M., Bahri, O., Béjaoui, M., & Dellagi, K. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.3.1203-1211.2003 · Cited by 16
Recombinant Sabin environmental isolates in Greece and Cyprus
Paximadi, E., Karakasiliοtis, I., Papaventsis, D. C., Papageorgiou, G. T., & Markoulatos, P. (2007) · Journal of Applied Microbiology · doi:10.1111/j.1365-2672.2007.03649.x · Cited by 15
Dedepsidis, E., Karakasiliοtis, I., Paximadi, E., Kyriakopoulou, Z., Komiotis, D., & Markoulatos, P. (2006) · Virus Genes · doi:10.1007/s11262-005-0055-3 · Cited by 16
Estimating the Risk of Re-Emergence after Stopping Polio Vaccination
Sasaki, A., Haraguchi, Y., & Yoshida, H. (2012) · Frontiers in Microbiology · doi:10.3389/fmicb.2012.00178 · Cited by 16
Annual report of the Australian National Poliovirus Reference Laboratory, 2007
Roberts, J. A., Grant, K. A., Ibrahim, A., & Thorley, B. R. (2008) · Communicable Diseases Intelligence · doi:10.33321/cdi.2008.32.31 · Cited by 14
Devaux, C. A., Pontarotti, P., Levasseur, A., Colson, P., & Raoult, D. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1284337 · Cited by 16
Shulman, L. M. (2012) · Journal of Bioterrorism & Biodefense · doi:10.4172/2157-2526.s4-004 · Cited by 14
Wang, H., Luo, H., Li, L., Fan, C., Hao, L., Ma, C., Su, Q., Yang, H., Reilly, K. H., Wang, H., et al. (2017) · BMC Infectious Diseases · doi:10.1186/s12879-017-2849-z · Cited by 12
Error Frequencies of Picornavirus RNA Polymerases: Evolutionary Implications for Virus Populations
Domingo, E., Baranowski, É., Escarmı́s, C., Sobrino, F., & Holland, J. J. (2014) · ASM Press eBooks · doi:10.1128/9781555817916.ch23 · Cited by 12
Current polio status in the world
Lima, E. S., Romero, E. C., & Granato, C. F. H. (2021) · Jornal Brasileiro de Patologia e Medicina Laboratorial · doi:10.5935/1676-2444.20210022 · Cited by 13
The Mechanism of Poliovirus Eradication
Kew, O. M., & Pallansch, M. A. (2014) · ASM Press eBooks · doi:10.1128/9781555817916.ch39 · Cited by 12
Self-citationIntroduction to the Human Enteroviruses and Parechoviruses
Romero, J. R., & Modlin, J. F. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00172-7 · Cited by 11
Kemball, C. C., Fujinami, R. S., & Whitton, J. L. (2014) · ASM Press eBooks · doi:10.1128/9781555816698.ch19 · Cited by 12
Virus Evolution in Prolonged Infections of Immunocompromised Individuals
Raglow, Z., & Lauring, A. S. (2024) · Clinical Chemistry · doi:10.1093/clinchem/hvae150 · Cited by 12
The future of polio eradication
Hull, H. F. (2001) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(01)00143-8 · Cited by 10
Genetic features of polioviruses isolated in Tunisia, 1991–2006
Boubaker, S., Yahia, A. B., Bahri, O., Morel, V., Balanant, J., Delpeyroux, F., & Triki, H. (2007) · Journal of Clinical Virology · doi:10.1016/j.jcv.2007.10.002 · Cited by 10
Natural Clearance of Prolonged VDPV Infection in a Child With Primary Immunodeficiency Disorder
Mohanty, M. C., Madkaikar, M. R., Desai, M., Aluri, J., Varose, S. Y., Taur, P. D., Sharma, D. K., Nalavade, U. P., Rane, S. V., Gupta, M., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01567 · Cited by 10
van de Ven, A., van Konijnenburg, D. P. H., Wensing, A. M. J., & van Montfrans, J. M. (2011) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-011-8292-9 · Cited by 10
Sazzad, H. M. S., Rainey, J. J., Mach, O., Sutter, R. W., Diordista, S., Kawser, C. A., Mobarak, R., Alam, D., Chowdhury, M. A., Hossain, J., et al. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.06.017 · Cited by 10
Self-citationKohler, K. A., Hlady, W. G., Banerjee, K., & Sutter, R. W. (2003) · International Journal of Epidemiology · doi:10.1093/ije/dyg011 · Cited by 10
Self-citationEstívariz, C. F., Krow‐Lucal, E., & Mach, O. (2024) · Pathogens · doi:10.3390/pathogens13121128 · Cited by 9
Sazzad, H. M. S., Rainey, J. J., Kahn, A.-L., Mach, O., Liyanage, J. B. L., Alam, A. N., Kawser, C. A., Hossain, A., Sutter, R. W., & Luby, S. P. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu221 · Cited by 9
Self-citationEl-Sayed, Z. F., & Mach, O. (2016) · Journal of Vaccines & Vaccination · doi:10.4172/2157-7560.1000331 · Cited by 8
Persistent Infections by Picornaviruses
Colbère-Garapin, F., Pelletier, I., & Ouzilou, L. (2014) · ASM Press eBooks · doi:10.1128/9781555817916.ch35 · Cited by 9
Rahimi, P., Tabatabaie, H., Gouya, M. M., Zahraie, M., Mahmudi, M., Ziaie, A., Samimi‐Rad, K., Shahmahmudi, S., Musavi, T., Mokhtari‐Azad, T., et al. (2007) · Journal of Clinical Virology · doi:10.1016/j.jcv.2007.04.017 · Cited by 8
Vaccine associated paralytic poliomyelitis unmasking common variable immunodeficiency
Gomber, S., Arora, V., & Dewan, P. (2017) · Indian Pediatrics · doi:10.1007/s13312-017-1038-x · Cited by 8
Hassan, J., Wangai, L. N., Borus, P., Khayeka‐Wandabwa, C., Karani, L. W., Kithinji, M., & Kiptoo, M. K. (2017) · BMC Research Notes · doi:10.1186/s13104-017-2843-y · Cited by 7
Kew, O. M. (2014) · Springer eBooks · doi:10.1007/978-1-4899-7448-8_13 · Cited by 8
Self-citationSullivan, K. E., Bassiri, H., Bousfiha, A. A., Costa‐Carvalho, B. T., Freeman, A. F., Hagin, D., Lau, Y., Lionakis, M. S., Moreira, I., Pinto, J. A., et al. (2017) · Journal of Clinical Immunology · doi:10.1007/s10875-017-0426-2 · Cited by 9
Use of mutational pattern in 5′-NCR and VP1 regions of polioviruses for molecular diagnosis
Pliaka, V., Dedepsidis, E., Kyriakopoulou, Z., Papadopoulou, I., Levidiotou, S., & Markoulatos, P. (2007) · Molecular and Cellular Probes · doi:10.1016/j.mcp.2007.01.004 · Cited by 8
Shulman, L. M. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5719-0_10 · Cited by 7
Okonko, I. O., Babalola, E. T., Adedeji, A. O., Onoja, A. B., Ogun, A. A., Nkang, A. O., & Adu, F. D. (2008) · Biotechnology and Molecular Biology Reviews · doi:10.5897/bmbr2008.0012 · Cited by 7
Enterovirus Infection in Immunocompromised Hosts
Schaenman, J. M. D., Ho, D. Y., Baden, L. R., & Safdar, A. (2019) · Springer eBooks · doi:10.1007/978-1-4939-9034-4_42 · Cited by 7
Galal, N. M., Bassiouni, L., Nasr, E. M. E. M., & Abdelmeguid, N. (2012) · The Journal of Infection in Developing Countries · doi:10.3855/jidc.2372 · Cited by 7
Eradication and cessation of programmes
Minor, P. D. (2002) · British Medical Bulletin · doi:10.1093/bmb/62.1.213 · Cited by 7
Okonko, I. O., Ogun, A. A., Adedeji, A. O., Akanbi, O. A., Udeze, A. O., & Motayo, B. O. (2009) · Scientific Research and Essays · doi:10.5897/sre.9000269 · Cited by 6
Vaccine Associated Paralytic Poliomyelitis
Mittal, S. K., & Mathew, J. L. (2003) · The Indian Journal of Pediatrics · doi:10.1007/bf02723161 · Cited by 7
Costa‐Carvalho, B. T., Sullivan, K. E., Fontes, P. M., Nobre, F. A., Gonzales, I. G. S., Lima, E. S., Granato, C. F. H., & de Moraes‐Pinto, M. I. (2018) · Journal of Clinical Immunology · doi:10.1007/s10875-018-0531-x · Cited by 5
Immune Responses to DNA Vaccines: Induction of CD8+ T Cells
Leifert, J. A., & Whitton, J. L. (2003) · Springer eBooks · doi:10.1007/978-1-4615-0105-3_5 · Cited by 6
Commentary: Poliomyelitis and unnecessary injections
Halsey, N. A. (2003) · International Journal of Epidemiology · doi:10.1093/ije/dyg071 · Cited by 5
Sullivan, K. E., Bassiri, H., Bousfiha, A. A., Costa‐Carvalho, B. T., Freeman, A. F., Hagin, D., Lau, Y., Lionakis, M. S., Moreira, I., Pinto, J. A., et al. (2017) · Journal of Clinical Immunology · doi:10.1007/s10875-017-0436-0 · Cited by 5
Enteroviral Infection in Greek AIDS Patients
Papaventsis, D. C., Markoulatos, P., Mangafas, N., Lazanas, M., & Levidiotou-Stefanou, S. (2004) · Molecular Diagnosis · doi:10.1007/bf03260042 · Cited by 4
Introduction to the Enteroviruses and Parechoviruses
Modlin, J. F. (2010) · Elsevier eBooks · doi:10.1016/b978-0-443-06839-3.00170-3 · Cited by 4
Shulman, L. M. (2012) · Springer eBooks · doi:10.1007/978-1-4419-0851-3_839 · Cited by 4
WHO global action plan for laboratory containment of wild polioviruses (Second edition)
Shimizu, H., Yoshida, H., & Miyamura, T. (2005) · Uirusu · doi:10.2222/jsv.55.161 · Cited by 3
Annual report of the Australian National Poliovirus Reference Laboratory, 2003
Brussen, K. A., Stambos, V., & Thornley, B. R. (2004) · Communicable Diseases Intelligence · doi:10.33321/cdi.2004.28.38 · Cited by 3
The Epidemiology of Poliomyelitis Deconstructed
Bhardwaj, S. (2016) · UC Merced Undergraduate Research Journal · doi:10.5070/m482030788 · Cited by 2
Estívariz, C. F., Burns, C. C., & Macklin, G. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79058-1.00050-5 · Cited by 2
Boubaker, S., Ould-Mohamed-Abdallah, M. V., Benyahia, A., & Triki, H. (2009) · Pathologie Biologie · doi:10.1016/j.patbio.2009.01.004 · Cited by 2
Sabin Vaccine in Poliomyelitis Eradication: Achievements and Risks
Nafi, O., & Ramadan, B. (2019) · Journal of Pure and Applied Microbiology · doi:10.22207/jpam.13.1.45 · Cited by 2
Annual report of the Australian National Poliovirus Reference Laboratory, 2002
Thorley, B. R., Brussen, K. A., Stambos, V., & Kelly, H. (2003) · Communicable Diseases Intelligence · doi:10.33321/cdi.2003.27.59 · Cited by 2
Shulman, L. M., Weil, M., Somech, R., Stauber, T., Indenbaum, V., Rahav, G., Mendelson, E., & Sofer, D. (2020) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piaa053 · Cited by 1
Modlin, J. F. (2010) · Elsevier eBooks · doi:10.1016/b978-0-443-06839-3.00171-5 · Cited by 1
Annual report of the Australian National Poliovirus Reference Laboratory, 2009
Roberts, J. A., Hobday, L. K., Polychronopoulos, S., & Ibrahim, A. (2010) · Communicable Diseases Intelligence · doi:10.33321/cdi.2010.34.27 · Cited by 1
Wilton, T. (2012) · doi:10.25560/10677 · Cited by 1
Immunoprophylaxis of Viral Diseases
Hadler, S. C., & Seward, J. F. (2010) · Wiley eBooks · doi:10.1002/9780470688618.taw0273 · Cited by 1
Circulating vaccine-derived polioviruses: current state of
Kew, M. C., Wright, P. F., Agol, V. I., Delpeyroux, F., Shimizu, H., Nathanson, N., & Pallansch, M. A. (2004) · Cited by 1
Self-citationAnnual report of the Australian National Poliovirus Reference Laboratory 2005
Brussen, K. A., Roberts, J., Ibrahim, A., Stambos, V., & Thorley, B. R. (2006) · Communicable Diseases Intelligence · doi:10.33321/cdi.2006.30.29 · Cited by 1
Suzuki, Y., Wyndham, A., & Gojobori, T. (2003) · Wiley eBooks · doi:10.1002/0470022620.bbc12 · Cited by 1
Pavlov, D. N. (2004) · UpSpace Institutional Repository (University of Pretoria)
Inmunodeficiencia variable común Enfoque en aspectos de inmunoprofilaxis activa
Manfredi, R., & Calza, L. (2007) · Alergia, Asma e Inmunología Pediátricas
Gunasena, S., SILVA, R. D., Ratnayake, D., Kumarasiri, C., & Deshpande, J. M. (2014) · Sri Lankan Journal of Infectious Diseases · doi:10.4038/sljid.v4i2.6672
Quantitative analysis of trade-offs and model input sensitivities in public health
Tebbens, R. J. D. (2005)
Erradicación de la poliomielitis
Aristegui, F. J., & de, J. (2003) · Anales de Pediatría
SHORT REPORT COMMON VARIABLE IMMUNODEFICIENCY - FOCUS ON SOME ACTIVE IMMUNOPROPHYLAXIS ISSUES
Manfredi, R., Calza, L., & Mater, A. (2008)
Metadata
- Authors
- Kew, O. M., Sutter, R. W., Nottay, B. K., McDonough, M. J., Prevots, D. R., Quick, L., & Pallansch, M. A.
- Affiliations
- National Center for Infectious Diseases (US)
- <!--label omitted: 2-->Divisions of Eradication of Vaccine-Preventable Diseases2 and
- Centers for Disease Control and Prevention (US)
- Venue
- Journal of Clinical Microbiology
- Publisher
- American Society for Microbiology
- Published
- 1998-10
- Volume
- 36
- Issue
- 10
- Pages
- 2893-2899
- ISSN
- 0095-1137 (ISSN-L)
- 1098-660X
- PMC
- PMC105084
- OpenAlex
- W2159041114
- Cited by
- 213
- References
- 36
- Citations by year
- 2024: 4 · 2023: 3 · 2022: 1 · 2021: 1 · 2020: 4 · 2019: 6 · 2018: 3 · 2017: 9 · 2016: 4 · 2015: 3 · 2014: 16 · 2013: 6 · 2012: 14
- FWCI
- 6.02
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Microbiology (publishedVersion)
- PubMed Central (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Evolution and Genetic Dynamics
- Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
- Keywords
- poliovirus type 1, vaccine-derived poliovirus, common variable immunodeficiency, viral evolution, poliomyelitis, oral polio vaccine, polio eradication
- MeSH terms
- Adult, Amino Acid Sequence, Base Sequence, Capsid, Child, Feces, Follow-Up Studies, Humans, Immunologic Deficiency Syndromes, Male, Molecular Sequence Data, Phylogeny, Viral Plaque Assay, Poliomyelitis, Poliovirus Vaccine, Oral, RNA, Viral, Genetic Variation, Virus Replication, Polymerase Chain Reaction, Sequence Alignment, Sequence Homology, Amino Acid, Poliovirus, Evolution, Molecular, Capsid Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
